Cargando…
Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
KRAS mutations are one of the most common gene mutations linked to cancer, presenting in approximately 25% of all tumors, especially pancreatic, lung, and colorectal cancers. Mutant KRAS has long been considered an undruggable target, stalling progress in direct KRAS targeting for many years, while...
Autores principales: | Liu, Huiqin, Qian, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771556/ https://www.ncbi.nlm.nih.gov/pubmed/35154489 http://dx.doi.org/10.7150/thno.67889 |
Ejemplares similares
-
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019) -
Macropinocytosis Exploitation by Cancers and Cancer Therapeutics
por: Ha, Kevin D., et al.
Publicado: (2016) -
Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells
por: Jeong, Seokmin, et al.
Publicado: (2018) -
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
por: Hou, Pingping, et al.
Publicado: (2021) -
Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide
por: Colin, Margaux, et al.
Publicado: (2019)